Julie Scallen > Latham & Watkins LLP > Boston, United States > Lawyer Profile
Latham & Watkins LLP Offices
200 CLARENDON STREET
BOSTON MA 02116
MASSACHUSETTS
United States
Julie Scallen

Work Department
Julie Scallen is a partner in the Boston office of Latham & Watkins and serves as Corporate Department Chair for the Boston office. She focuses her practice on mergers and acquisitions and private equity transactions. Ms. Scallen represents public and private companies and private equity funds in acquisitions, leveraged buyouts, dispositions, private equity and venture capital financings, strategic alliances, joint ventures and licensing transactions.
Lawyer Rankings
United States > Healthcare > Life sciences
(Leading partners)Latham & Watkins LLP works with a number of major players in the life sciences industry on transactions in the sector, handling both M&A and IPOs, in addition to assisting with business combinations and licensing deals. In addition to transactional expertise, the practice is adept at overseeing patent protection strategies and litigation for pharma, biotech and medical devices companies. In Washington DC, John Manthei
chairs the firm’s global life sciences group, specializing in the FDA regulatory process alongside vice chair Ben Haas, while also advising on the marketing of drugs and representing clients in Administrative Procedures Act litigation. Further litigation expertise comes in the shape of New York’s Arlene Chow and Chicago-based Terra Reynolds, with the former handling patent disputes concerning small molecule drugs and biologics, and the latter focusing on white collar defence and government investigations. In Silicon Valley, Shayne Kennedy is noted for his capital markets practice, advising on public and private securities offerings by life sciences clients. Boston’s Julie Scallen oversees both M&A and private equity transactions, and Elizabeth Richards, William McConagha and Jennifer Bragg, based in the capital, assist with FDA and DEA product testing and approval procedures. Judith Hasko has left the firm.
Lawyer Rankings
- Leading partners United States > Healthcare > Life sciences
- Life sciences United States > Healthcare
Top Tier Firm Rankings
- Insurance > Advice to policyholders
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- Finance > Capital markets: high-yield debt offerings
- Antitrust > Cartel
- International trade and national security > CFIUS
- Antitrust > Civil litigation/class actions: defense
- Finance > Commercial lending
- Intellectual property > Copyright
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Energy > Energy transactions: electric power
- Energy > Energy transactions: oil and gas
- Environment > Environment: litigation
- Environment > Environment: regulatory
- Environment > Environment: transactional
- Finance > Fintech
- Real estate > Land use/zoning
- Environment > Environment: regulatory
- Environment > Environment: regulatory
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Dispute resolution > Financial services litigation
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Media, technology and telecoms > Media and entertainment: litigation
- Media, technology and telecoms > Media and entertainment: transactional
- Antitrust > Merger control
- Environment > Environment: regulatory
- Environment > Environment: regulatory
- Intellectual property > Patents: licensing
- Intellectual property > Patents: litigation (full coverage)
- Intellectual property > Patents: litigation (International Trade Commission)
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Finance > Project finance
- Real estate > Real estate
- Real estate > Real estate investment trusts (REITs)
- Energy > Renewable/alternative power
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Securities litigation: defense
- Industry focus > Sport
- Finance > Structured finance: derivatives and structured products
- Media, technology and telecoms > Technology transactions
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: contentious
- Tax > US taxes: non-contentious
Firm Rankings
- M&A/corporate and commercial > Corporate governance
- International trade and national security > Customs, export controls and economic sanctions
- Energy > Energy regulation: electric power
- Energy > Energy regulation: oil and gas
- Dispute resolution > General commercial disputes
- Government > Government contracts
- Insurance > Insurance: non-contentious
- Dispute resolution > International litigation
- Investment fund formation and management > Private equity funds (including venture capital)
- Healthcare > Service providers
- Finance > Structured finance: securitization
- M&A/corporate and commercial > Venture capital and emerging companies
- Dispute resolution > Financial services litigation
- Healthcare > Health insurers
- Dispute resolution > Leading trial lawyers
- Dispute resolution > International arbitration
- Intellectual property > Trademarks: litigation
- Finance > Financial services regulation
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Dispute resolution > Corporate investigations and white-collar criminal defense
- M&A/corporate and commercial > Shareholder activism